Portal Biotech secures £25m Series A led by NATO Innovation Fund and Earlybird to pioneer full-length protein sequencing

Portal Biotech is developing benchtop protein sequencing technology that reads full-length proteins at single-molecule resolution, enabling new insights for drug discovery, diagnostics and biosecurity research.